|Bid||0.00 x 1000|
|Ask||0.00 x 1100|
|Day's Range||83.31 - 85.12|
|52 Week Range||82.92 - 131.73|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||35.88|
|Earnings Date||Oct 25, 2022 - Oct 31, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||116.11|
Subscribe to Yahoo Finance Plus to view Fair Value for EW
From biotech to managed care, companies are tackling new challenges in science and business. Our healthcare roundtable experts pick 12 stocks that could win.
A system from Edwards Lifesciences that has been cleared by the Food and Drug Administration gives patients an alternative after years of a single company dominating the market.
Edwards Lifesciences Corporation (NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (TEER) therapies. The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR). Results from the CLASP IID pivotal trial were presented as a late-breaking clinical science session at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scient